Global Migraine Drugs Market (2018-2025)-GMI Research Global Migraine Drugs Market (2018-2025)-GMI Resea | Page 2

(Hospital Pharmacies, Retail Pharmacies and Others), and by Geography –
Opportunities & Forecast, 2018-2025
Migraine is a neurological disorder that causes severe pain in head and results in
nausea, vomiting, and extreme sensitivity to light and sound. The common types
of migraine are with aura and without aura that means classical migraines and
common migraines.
Download Sample Brochure : https://www.gmiresearch.com/sample-research-
report.php?rid=132
According to migraine trust website, in 2016, migraine headaches affected about
12.0% to 14.7% of population across the globe. Migraine has been categorized by
frequency and nature of attack into episodic migraine and chronic migraine as
per international as well regional guidelines. Migraine is an extraordinarily
prevalent neurological disease, affecting 39 million men, women and children in
the US and 1 billion worldwide. As per World Health Organization (WHO) in 2016,
about 50% of migraine disorders were reported, out of which, women patients
were more.
Rise in prevalence of migraine in the age group of 30 to 40 drives the migraine
drugs market. Moreover, increase in female population and surge in awareness
among patients related to prevention and treatment of migraine are the key
factors that augment the growth of the market. However, side effects like
fatigue, nausea, lowering of blood pressure, etc., associated with migraine drugs
is a factor that hinders the market growth. Migraine disorders are among the
most common disorders of the nervous system, mostly observed in adult
population. Furthermore, North America holds the largest share in the migraine
drugs market as it has large number of ageing population.
Various notable players operating in the global migraine drugs market include
Abbott Laboratories, Aegis Therapeutics, LLC, Aerial Biopharma LLC, Alder